Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label GOG. Show all posts
Showing posts with label GOG. Show all posts
Thursday, May 17, 2012

paywalled - Gynecologic Oncology - A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: GOG

›
ScienceDirect.com - Gynecologic Oncology - A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent ...
Wednesday, April 18, 2012

Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavi - GOGty Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy - Full Text View - ClinicalTrials.gov

›
 WebMd:   ACETYL - L - CARNITINE (including other names)                             ~~~~~~~~~~~~~~~~~~~~ This study is not yet ...
Saturday, January 07, 2012

U.S. - Planned Cooperative Group Merger Is Generating Concern - NCI clinical trials - gynecologic oncologists, funding, more common cancers, GOG....

›
A proposed overhaul of the National Cancer Institute’s clinical trials system has created anxiety among gynecologic researchers who fear p...
Thursday, December 29, 2011

Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: A GOG study

›
Sunday, May 08, 2011

abstract: A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian - GOG

›
Note: although a 3% difference of estimated recurrence rates (542 patients @ 3% = 16.26 patients/lives), the abstract does not allow for ...
Tuesday, April 12, 2011

OXiGENE, Inc. - OXiGENE Announces First Patient Enrolled in Phase 2 Study of ZYBRESTAT in Patients With Ovarian Cancer (comparing Avastin alone)

›
"SOUTH SAN FRANCISCO, Calif., April 11, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical co...
Wednesday, March 09, 2011

abstract: A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: (GOG 146Q)

›
Monday, February 28, 2011

Nuclear P27 (gene) expression in benign, borderline (LMP) and invasive tumors of the ovary and its association with prognosis: A GOG group study

›
Abstract Objective Nuclear p27 expression was examined in non-invasive and invasive ovarian tumors from a cross-sectional study, and c...
Monday, February 07, 2011

January 5, 2011 Gynecologic Oncology Group Survival - White Paper

›
January 5, 2011 Gynecologic Oncology Group Survival In 2010 cancerletter.com/downloads/20110203/download "In 2010, the Institute o...
Friday, January 21, 2011

Cantech Letter interviews Brad Thompson President and CEO of Oncolytics Biotech (Reolysin, GOG, clinical trials)

›
Wednesday, January 12, 2011

NCI Cancer Bulletin: (The GOG Rare Tumor Committee)

›
Comparing First-Line Therapies for Mucinous Ovarian or Fallopian Tube Cancer Name of the Trial Phase III Study of Carboplatin and Paclita...
Monday, September 13, 2010

media: Novel Study Using Reoviruses Against Ovarian Cancer Pushes Forward

›
Calgary-based Oncolytics Biotech Inc. recently announced that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase I...
Wednesday, August 18, 2010

Gynecologic Oncology Group quality assurance audits: analysis and initiatives for improvement — Clin Trials

›
Tuesday, May 18, 2010

A Comparison of Quality-of-Life Domains and Clinical Factors in Ovarian Cancer Patients: A Gynecologic Oncology Group Study

›
CONCLUSION: Ovarian cancer patients have decreased QOL in physical, functional, and emotional domains; however, they may compensate with in...
Tuesday, April 13, 2010

Thomas J. Herzog, MD, Columbia University College of Physicians and Surgeons talks about liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced malignancy/GOG reference to trials

›
Note: This is a repost of the video. Dr Herzog speaks briefly about the direction of GOG trials including the numerous drug combinations and...
Wednesday, March 31, 2010

Translational research in the Gynecologic Oncology

›
Friday, March 19, 2010

Translational research in the Gynecologic Oncology Group: Evaluation of ovarian cancer markers, profiles, and novel therapies.

›
Thursday, March 04, 2010

Gynecologic Oncology Group (GOG) Notifies CTI That Continuation of GOG-212 Pivotal Trial of OPAXIO Maintenance Therapy in Front Line Ovarian Cancer Remains High Priority - MarketWatch

›
press release March 4, 2010, 1:30 a.m. EST Gynecologic Oncology Group (GOG) Notifies CTI That Continuation of GOG-212 Pivotal Trial of OPAXI...